Early decrease of T-bet+ B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients

IF 3.3 4区医学 Q3 IMMUNOLOGY

Immunology letters Pub Date : 2024-12-04 DOI:10.1016/j.imlet.2024.106962

Francesca La Gualana , Giulio Olivieri , Begi Petriti , Licia Picciariello , Francesco Natalucci , Maddalena Sciannamea , Laura Gragnani , Umberto Basile , Milvia Casato , Francesca Romana Spinelli , Lucia Stefanini , Stefania Basili , Marcella Visentini , Fulvia Ceccarelli , Fabrizio Conti

{"title":"Early decrease of T-bet+ B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients","authors":"Francesca La Gualana , Giulio Olivieri , Begi Petriti , Licia Picciariello , Francesco Natalucci , Maddalena Sciannamea , Laura Gragnani , Umberto Basile , Milvia Casato , Francesca Romana Spinelli , Lucia Stefanini , Stefania Basili , Marcella Visentini , Fulvia Ceccarelli , Fabrizio Conti","doi":"10.1016/j.imlet.2024.106962","DOIUrl":null,"url":null,"abstract":"<div><div>Systemic lupus erythematosus (SLE) is characterized by B cell dysregulation and expansion of atypical B cells that may correlate with disease manifestations and activity. This study investigated the impact of subcutaneous (sc) Belimumab (BLM) on the peripheral B cell compartment and on the functional properties of CD21<sup>low</sup>, T-bet<sup>+</sup> and CD11c<sup>+</sup> atypical B cells, in 21 active SLE patients over a 12-month period. At baseline, active SLE patients displayed reduced unswitched IgM memory B cells and expansion of atypical B cells, compared to healthy donors and to SLE patients in remission. <em>sc</em> BLM therapy promptly restored B cell homeostasis with a reduction of T-bet<sup>+</sup> B cells, observed early in patients responsive to therapy. These findings highlight the pathogenic role of T-bet<sup>+</sup> B cells in SLE disease and suggest their potential utility as biomarker of clinical response.</div></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"272 ","pages":"Article 106962"},"PeriodicalIF":3.3000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165247824001366","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Systemic lupus erythematosus (SLE) is characterized by B cell dysregulation and expansion of atypical B cells that may correlate with disease manifestations and activity. This study investigated the impact of subcutaneous (sc) Belimumab (BLM) on the peripheral B cell compartment and on the functional properties of CD21^low, T-bet⁺ and CD11c⁺ atypical B cells, in 21 active SLE patients over a 12-month period. At baseline, active SLE patients displayed reduced unswitched IgM memory B cells and expansion of atypical B cells, compared to healthy donors and to SLE patients in remission. sc BLM therapy promptly restored B cell homeostasis with a reduction of T-bet⁺ B cells, observed early in patients responsive to therapy. These findings highlight the pathogenic role of T-bet⁺ B cells in SLE disease and suggest their potential utility as biomarker of clinical response.

查看原文本刊更多论文

在皮下贝利单抗期间早期T-bet+ B细胞的减少预测对系统性红斑狼疮患者治疗的反应。

系统性红斑狼疮（SLE）的特点是B细胞失调和非典型B细胞的扩增，这可能与疾病的表现和活动有关。本研究对21例活动性SLE患者进行了为期12个月的研究，研究了皮下（sc） Belimumab （BLM）对外周B细胞区和CD21low、T-bet+和CD11c+非典型B细胞功能特性的影响。在基线时，与健康供体和缓解期SLE患者相比，活动性SLE患者表现出未转换的IgM记忆B细胞减少和非典型B细胞扩增。sc BLM治疗迅速恢复B细胞稳态，减少T-bet+ B细胞，早期观察到患者对治疗有反应。这些发现强调了T-bet+ B细胞在SLE疾病中的致病作用，并表明它们作为临床反应的生物标志物的潜在效用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology letters 医学-免疫学

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

44 days

期刊介绍： Immunology Letters provides a vehicle for the speedy publication of experimental papers, (mini)Reviews and Letters to the Editor addressing all aspects of molecular and cellular immunology. The essential criteria for publication will be clarity, experimental soundness and novelty. Results contradictory to current accepted thinking or ideas divergent from actual dogmas will be considered for publication provided that they are based on solid experimental findings. Preference will be given to papers of immediate importance to other investigators, either by their experimental data, new ideas or new methodology. Scientific correspondence to the Editor-in-Chief related to the published papers may also be accepted provided that they are short and scientifically relevant to the papers mentioned, in order to provide a continuing forum for discussion.